GB201714307D0 - Treatment of neurodegenerative diseases - Google Patents

Treatment of neurodegenerative diseases

Info

Publication number
GB201714307D0
GB201714307D0 GBGB1714307.4A GB201714307A GB201714307D0 GB 201714307 D0 GB201714307 D0 GB 201714307D0 GB 201714307 A GB201714307 A GB 201714307A GB 201714307 D0 GB201714307 D0 GB 201714307D0
Authority
GB
United Kingdom
Prior art keywords
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1714307.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Ltd
Original Assignee
BenevolentAI Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BenevolentAI Ltd filed Critical BenevolentAI Ltd
Priority to GBGB1714307.4A priority Critical patent/GB201714307D0/en
Publication of GB201714307D0 publication Critical patent/GB201714307D0/en
Priority to PCT/GB2018/052514 priority patent/WO2019048852A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1714307.4A 2017-09-06 2017-09-06 Treatment of neurodegenerative diseases Ceased GB201714307D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1714307.4A GB201714307D0 (en) 2017-09-06 2017-09-06 Treatment of neurodegenerative diseases
PCT/GB2018/052514 WO2019048852A1 (en) 2017-09-06 2018-09-05 Treatment of neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1714307.4A GB201714307D0 (en) 2017-09-06 2017-09-06 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
GB201714307D0 true GB201714307D0 (en) 2017-10-18

Family

ID=60050741

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1714307.4A Ceased GB201714307D0 (en) 2017-09-06 2017-09-06 Treatment of neurodegenerative diseases

Country Status (2)

Country Link
GB (1) GB201714307D0 (en)
WO (1) WO2019048852A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202016708D0 (en) * 2020-10-21 2020-12-02 Univ Birmingham Uses of chk2 inhibitors
GB202016710D0 (en) * 2020-10-21 2020-12-02 Univ Birmingham Treatment of eye conditions
WO2023212411A1 (en) * 2022-04-29 2023-11-02 Indiana University Research And Technology Corporation Methods of treating neuropathy using foretinib and compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases

Also Published As

Publication number Publication date
WO2019048852A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL269106A (en) Methods of treating neurodegenerative diseases
EP3227330C0 (en) Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
IL265902A (en) Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
GB201804514D0 (en) Treatment of pyroptosis
EP3273955A4 (en) Treatment of respiratory diseases
ZA201903003B (en) Treatment of neurological diseases
GB201516905D0 (en) Treatment of Neurodegenerative diseases
HK1258994A1 (en) Methods for treatment of diseases
GB201412578D0 (en) Treatment of neurological diseases
GB201804515D0 (en) Treatment of necroptosis
GB201714307D0 (en) Treatment of neurodegenerative diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
EP3606522C0 (en) Novel treatment of mitochondrial diseases
EP3283457A4 (en) Compounds and methods for the treatment of neurodegenerative diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
IL259381B (en) Mirabegron for the treatment of retinal diseases
EP3534954A4 (en) Compounds for treatment of neurodegenerative diseases
SI3302499T1 (en) Treatment of mitochondrial diseases
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201714303D0 (en) Treatment of neurodegenerative diseases
GB201714316D0 (en) Treatement of neurodegenerative diseases
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
EP3426280A4 (en) Methods of treating neurodegenerative diseases
GB201704666D0 (en) Treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)